Effects of canrenone in patients with metabolic syndrome. - Test2 - elhamkhani - TriplyDB

Effects of canrenone in patients with metabolic syndrome.

Effects of canrenone in patients with metabolic syndrome.

http://www.wikidata.org/entity/Q47681681

about

Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.Interfering with mineralocorticoid receptor activation: the past, present, and future Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial Ammonia, like K(+), stimulates the Na(+), K(+), 2 Cl(-) cotransporter NKCC1 and the Na(+),K(+)-ATPase and interacts with endogenous ouabain in astrocytes.A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.The effects of canrenone on inflammatory markers in patients with metabolic syndrome.Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients

P2860

Q33713860-97CA8519-D5C6-49FC-92F8-A199F53B1D48 Q34019947-6D34840A-DC05-4C6D-9781-2ED3B1CE17AC Q35916952-D7873758-5987-420B-9021-743DB68EFAD4 Q38220273-BFFE53D9-37C0-4FBB-AE24-0ABA541D410E Q47122991-DDEC78A3-07EB-4C5A-849B-A08F10FCF87E Q48484033-334EB1F7-AE2A-4C66-814A-AD588A72F9CD Q51061323-C849AFD8-5169-4A1E-938D-E992BD1D460B Q58706911-37566D17-4F9D-45A2-88FF-08ABF2A32C06

P2860

Effects of canrenone in patients with metabolic syndrome.

http://www.wikidata.org/entity/Q47681681

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Effects of canrenone in patients with metabolic syndrome.

@en

Effects of canrenone in patients with metabolic syndrome.

@nl

type

label

Effects of canrenone in patients with metabolic syndrome.

@en

Effects of canrenone in patients with metabolic syndrome.

@nl

prefLabel

Effects of canrenone in patients with metabolic syndrome.

@en

Effects of canrenone in patients with metabolic syndrome.

@nl

P1433

Q47681681-295B5016-CE61-4AF3-8029-5B33E57A444A

P1476

Q47681681-C6412E8F-BF9A-4255-8D2C-2985899C528A

P2093

Q47681681-50657C1F-43DF-446B-89AE-3C19EB917950

Q47681681-52827993-667C-443B-AAEA-C8B618E842C2

Q47681681-D192A187-5ACD-41E7-9441-C8557F94356F

Q47681681-EF6DBE6C-57BB-4731-896A-55EFCF490A5D

P2860

Q47681681-032509E2-AEAA-4493-BEDC-D653168F353D

Q47681681-036F1D2D-0077-483E-A904-C6A247D42906

Q47681681-06D1DAB4-3387-4D15-9692-145C52AC5D46

Q47681681-18DB401F-99A2-4439-A669-E6F632AE6C19

Q47681681-1A5010F2-0BE8-407E-A587-232AC954CA3E

Q47681681-1CA348B3-65CE-4EE0-B67E-33D9A1239908

Q47681681-216A8159-C596-4684-A39E-AD188BB3D7A7

Q47681681-29F9524F-A54C-4802-AE74-26E0AEAEA8B7

Q47681681-2CB97101-5D65-4CAF-AA1A-F694735C93FC

Q47681681-2FCA0362-2E91-4D39-9B9F-AC08077F4639

P304

Q47681681-1E302F49-46D3-4ECF-91FB-294C769D1247

P31

Q47681681-E4EFD9AC-211F-4152-8A38-9889C335E6CA

P356

Q47681681-A3232EC9-1BB0-428A-8A8D-2A5238EC1219

P407

Q47681681-BB800893-7A5C-4094-AB45-8AB6A7905C6A

P433

Q47681681-040B69DF-69A2-4773-B684-686051B639EF

P478

Q47681681-DACCE3B3-D257-408C-AEF3-AF1386825EA3

P50

Q47681681-6B2B672B-26F4-41BE-BA11-523CA975FC1A

Q47681681-8EE39938-16C9-4DB0-8C00-FBF3FC921571

Q47681681-CF90A7EF-AC68-4F8F-8466-EFB4CC54E1D3

P577

Q47681681-643B67FF-2543-4BA1-9574-C13F98B98F5B

P698

Q47681681-5BF0446C-554A-4F61-923D-6DE1C3118C8B

P921

Q47681681-EDD312CB-8A85-4448-8AB8-CD675AA68103

P356

14656566.2013.832756

P1433

Expert Opinion on Pharmacotherapy

P1476

Effects of canrenone in patients with metabolic syndrome

@en

P2093

Angela D'Angelo

http://www.w3.org/2001/XMLSchema#string

Davide Romano

http://www.w3.org/2001/XMLSchema#string

Elena Fogari

http://www.w3.org/2001/XMLSchema#string

Lucio Bianchi

http://www.w3.org/2001/XMLSchema#string

P2860

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

The ubiquitous mineralocorticoid receptor: clinical implications

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

Use and abuse of HOMA modeling

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

The role of TNFalpha and TNF receptors in obesity and insulin resistance.

P304

2161-2169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.832756

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Pamela Maffioli

Giuseppe Derosa

Aldo Bonaventura

P577

2013-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23984806

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome